I-Mab (NASDAQ:IMAB) Short Interest Update

I-Mab (NASDAQ:IMAB - Get Free Report) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 936,000 shares, an increase of 20.0% from the January 31st total of 780,100 shares. Based on an average daily volume of 400,700 shares, the days-to-cover ratio is presently 2.3 days.

I-Mab Trading Down 4.2 %

IMAB stock traded down $0.04 during trading on Monday, hitting $0.82. The company had a trading volume of 75,486 shares, compared to its average volume of 315,225. I-Mab has a 52-week low of $0.76 and a 52-week high of $2.00. The company has a 50 day simple moving average of $0.98 and a 200-day simple moving average of $1.07.

Institutional Trading of I-Mab

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Caligan Partners LP lifted its position in I-Mab by 3.7% during the third quarter. Caligan Partners LP now owns 3,499,330 shares of the company's stock valued at $4,339,000 after acquiring an additional 124,539 shares during the last quarter. Garden State Investment Advisory Services LLC purchased a new position in I-Mab during the 3rd quarter worth $179,000. XTX Topco Ltd increased its position in I-Mab by 140.8% during the 3rd quarter. XTX Topco Ltd now owns 43,039 shares of the company's stock valued at $53,000 after buying an additional 25,163 shares in the last quarter. Millennium Management LLC raised its stake in I-Mab by 763.1% in the fourth quarter. Millennium Management LLC now owns 97,749 shares of the company's stock valued at $83,000 after buying an additional 86,424 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in I-Mab in the fourth quarter valued at about $93,000. Institutional investors own 38.38% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several research firms recently issued reports on IMAB. HC Wainwright reissued a "buy" rating and issued a $8.00 target price on shares of I-Mab in a report on Friday, November 15th. Brookline Capital Management upgraded I-Mab to a "strong-buy" rating in a research report on Thursday, February 27th.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.